Should I Buy REVB? REVB 2026 Analysis

Should You Buy Revelation Biosciences Inc (REVB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.960

1 Day change

-5.88%

52 Week Range

40.080

Analysis Updated At

2026/04/24

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Revelation Biosciences Inc (REVB) is not a strong buy for a beginner, long-term investor at this time. While the stock has a Buy rating from analysts and a positive pre-market price movement, the financials show significant losses, and technical indicators suggest a bearish trend. Additionally, there are no strong trading signals or recent news catalysts to support immediate investment.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 42.923, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels, with a pivot at 1.156 and resistance at 1.273. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

Analyst Jonathan Aschoff from Roth Capital maintains a Buy rating with a $16 price target, citing positive results from the Gemini trial and sufficient funding into Q1 2027.

Neutral/Negative Catalysts

The stock has a high chance of declining in the next month (-10.76%), and financial performance remains weak with negative net income and EPS. There are no significant hedge fund or insider trading trends, and no recent news or congress trading data to act as a catalyst.

Financial Performance

In Q4 2025, revenue remained at $0, net income improved to -$2,511,006 (up 45.50% YoY), but EPS dropped significantly to -1.64 (-97.25% YoY). The gross margin was 0, showing no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Roth Capital maintains a Buy rating with a reduced price target of $16 (from $20). Analysts highlight the positive safety and efficacy data from the Gemini trial, but the firm’s financials and funding limitations are noted.

Analyst Rating

Wall Street analysts forecast REVB stock price to rise

Buy

Hold

Sell

Current: 1.020

Low

Averages

High

Current: 1.020

Low

Averages

High

Roth Capital

Jonathan Aschoff

Buy

maintain

$16

AI Analysis

2026-03-30

Reason

Roth Capital

Jonathan Aschoff

Price Target

$16

AI Analysis

2026-03-30

maintain

Buy

Reason

Roth Capital analyst Jonathan Aschoff says Revelation Biosciences showed data from all Phase 1b PRIME trial patients showing that Gemini was similarly effective in reducing inflammatory cytokine levels, and restoring immunocompetence in chronic kidney disease patient peripheral blood mononuclear cells regardless of background inflammation levels. Gemini significantly reduced the number of elevated cytokines at all measured timepoints after a single dose out to seven days, the analyst tells investors in a research note. Roth says the results show Gemini's "broad effect." It keep a Buy rating on the shares with a $16 price target. The stock in late day trading is up 6% to $1.20.

Roth Capital

Buy

downgrade

$20 -> $16

2026-02-27

Reason

Roth Capital

Price Target

$20 -> $16

2026-02-27

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on Revelation Biosciences to $16 from $20 but keeps a Buy rating on the shares. The company ended 2025 with pro forma cash of $17.3M, enough funding into Q1 of 2027, the analyst tells investors in a research note. The firm further cites the Gemini trial safety data, which was well-tolerated at the target dose with all adverse events reported as mild at that dose and including transient headache, chills, loose stool, and body aches.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REVB

Unlock Now

REVB Should I Buy

REVB Should I Buy

Should You Buy Revelation Biosciences Inc (REVB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch